Urol. praxi, 2014; 15(3): 115-119

Targeted therapy of metastatic renal cell carcinoma and treatment sequences: a current view

MUDr.Alexandr Poprach, Ph.D.¹, doc.MUDr.Tomáš Büchler, Ph.D.², MUDr.Radek Lakomý, Ph.D.¹, MUDr.Jiří Tomášek, Ph.D.¹

¹ Klinika komplexní onkologické péče, Masarykova univerzita v Brně, LF a Masarykův onkologický ústav

² Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Advanced or metastatic inoperable renal cell carcinoma (mRCC) remains an incurable disease despite significant advances in systemic



treatment: Currently, there are seven targeted agents available in the Czech Republic. Sunitinib, pazopanib, temsirolimus, or bevacizumab/

interferon-α can be used as first-line therapy, everolimus, axitinib, sorafenib, or (in selected patients) sunitinib can be used in the second

line. Everolimus can also be used for third-line treatment. The choice of a first-line targeted agent is influenced by results of prospective

randomised clinical trials as well as clinical status of the patient and therapeutic intent. Recommendations for second- and third-line

therapy contain many areas of uncertainty although there are some randomised and non-randomised studies that have provided guidance

into optimal treatment selection. Nevertheless, sequential therapy of mRCC remains hotly debated in the oncology community.

Keywords: targeted therapy, renal cell carcinoma, sequential treatment

Published: July 1, 2014  Show citation